| Literature DB >> 20976140 |
Heather N Reich1, David Tritchler, Daniel C Cattran, Andrew M Herzenberg, Felix Eichinger, Anissa Boucherot, Anna Henger, Celine C Berthier, Viji Nair, Clemens D Cohen, James W Scholey, Matthias Kretzler.
Abstract
Proteinuria is the most important predictor of outcome in glomerulonephritis and experimental data suggest that the tubular cell response to proteinuria is an important determinant of progressive fibrosis in the kidney. However, it is unclear whether proteinuria is a marker of disease severity or has a direct effect on tubular cells in the kidneys of patients with glomerulonephritis. Accordingly we studied an in vitro model of proteinuria, and identified 231 "albumin-regulated genes" differentially expressed by primary human kidney tubular epithelial cells exposed to albumin. We translated these findings to human disease by studying mRNA levels of these genes in the tubulo-interstitial compartment of kidney biopsies from patients with IgA nephropathy using microarrays. Biopsies from patients with IgAN (n = 25) could be distinguished from those of control subjects (n = 6) based solely upon the expression of these 231 "albumin-regulated genes." The expression of an 11-transcript subset related to the degree of proteinuria, and this 11-mRNA subset was also sufficient to distinguish biopsies of subjects with IgAN from control biopsies. We tested if these findings could be extrapolated to other proteinuric diseases beyond IgAN and found that all forms of primary glomerulonephritis (n = 33) can be distinguished from controls (n = 21) based solely on the expression levels of these 11 genes derived from our in vitro proteinuria model. Pathway analysis suggests common regulatory elements shared by these 11 transcripts. In conclusion, we have identified an albumin-regulated 11-gene signature shared between all forms of primary glomerulonephritis. Our findings support the hypothesis that albuminuria may directly promote injury in the tubulo-interstitial compartment of the kidney in patients with glomerulonephritis.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20976140 PMCID: PMC2956647 DOI: 10.1371/journal.pone.0013451
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Genes differentially expressed in cells exposed to albumin.
|
|
| ||
| BIN1 | bridging integrator 1 | INHBA | inhibin, beta A (activin A, activin AB alpha polypeptide) |
| CDK2AP1 | CDK2-associated protein 1 | KPNA2 | karyopherin alpha 2 (RAG cohort 1, importin alpha 1) |
| CDKN1A | cyclin-dependent kinase inhibitor 1A (p21, Cip1) | MSH2 | mutS homolog 2, colon cancer, nonpolyposis type 1 (E. coli) |
| CFLAR | CASP8 and FADD-like apoptosis regulator | PTHLH | parathyroid hormone-like hormone TFDP1 transcription factor Dp-1 |
| CROP | cisplatin resistance-associated overexpressed protein | TFDP2 | transcription factor Dp-2 (E2F dimerization partner 2) |
| DAPK1 | death-associated protein kinase 1 | TYMS | thymidylate synthetase |
| DUSP5,6 | dual specificity phosphatase 5,6 | ||
| GLRX | glutaredoxin (thioltransferase) |
| |
| HTRA2 | HtrA serine peptidase 2 | HMGB2 | high-mobility group box 2 |
| IER2 | immediate early response 2 | NR2F2 | nuclear receptor subfamily 2, group F, member 2 |
| IER3 | immediate early response 3 | RGS4 | regulator of G-protein signaling 4 |
| IGFBP3 | insulin-like growth factor binding protein 3 | S100A2 | S100 calcium binding protein A2 |
| MBD4 | methyl-CpG binding domain protein 4 | SPRY2 | sprouty homolog 2 (Drosophila) |
| MCL1 | myeloid cell leukemia sequence 1 (BCL2-related) | SPRY4 | sprouty homolog 4 (Drosophila) |
| NDRG1 | N-myc downstream regulated gene 1 | ||
| SFN | stratifin |
| |
| THBD | thrombomodulin | COL1A1 | collagen, type I, alpha 1 |
| CYR61 | cysteine-rich, angiogenic inducer, 61 | ||
|
| KRT18 | keratin 18 | |
| ADFP | adipose differentiation-related protein | PLAU | plasminogen activator, urokinase |
| CCL20 | chemokine (C-C motif) ligand 20 | PLAUR | plasminogen activator, urokinase receptor |
| DNAJC9 | DnaJ (Hsp40) homolog, subfamily C, member 9 | SERPINE1 | serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 |
| HSPB8 | heat shock 22kDa protein 8 | ||
| IRF8 | interferon regulatory factor 8 |
| |
| SEMA4D | sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4D | ACSL3 | acyl-CoA synthetase long-chain family member 3 |
| UPP1 | uridine phosphorylase 1 | FDFT1 | farnesyl-diphosphate farnesyltransferase 1 |
| HMGCR | 3-hydroxy-3-methylglutaryl-Coenzyme A reductase | ||
|
| HMGCS1 | 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 (soluble) | |
| EGFR | epidermal growth factor receptor (erythroblastic leukemia viral v-erb-b oncogene homolog, avian) | LDLR | low density lipoprotein receptor (familial hypercholesterolemia) |
| EGR1 | early growth response 1 | LIPG | lipase, endothelial |
| ELF3 | E74-like factor 3 (ets domain transcription factor, epithelial-specific) | ||
| IGFBP3 | insulin-like growth factor binding protein 3 |
| |
| IL6 | interleukin 6 (interferon, beta 2) | TXNIP | thioredoxin interacting protein |
| IL8 | interleukin 8 | XDH | xanthine dehydrogenase |
| LIF | leukemia inhibitory factor (cholinergic differentiation factor) | ||
| PBEF1 | pre-B-cell colony enhancing factor 1 |
| |
| PHLDA2 | pleckstrin homology-like domain, family A, member 2 | BHLHB2 | basic helix-loop-helid domain containing, class B,2 |
| TNFSF10 | tumor necrosis factor superfamily, member 10 | CEBPD | CCAT/enhancer binding protein, delta |
| KDELC1 | KDEL (Lys-Asp-Glu-Leu) containing 1 | ||
|
| MAFF | v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian) | |
| CDC7 | CDC7 cell division cycle 7 (S. cerevisiae) | PSMD11 | proteasome (prosome, macropain) 26S subunit, non-ATPase, 11 |
| CDC27 | cell division cycle 27 | SAMD4 | sterile alpha motif domain containing 4 |
| CDK4 | cyclin-dependent kinase 4 | SLC19A2 | solute carrier family 19 (thiamine transporter) member 2 |
| G0S2 | G0/G1switch 2 | STEAP1 | 6 transmembrane epithelial antigen of prostate 1 |
| HBEGF | heparin-binding EGF-like growth factor | TARS | threonyl-tRNA synthetase |
| HK2 | hexokinase 2 | ZBED5 | zinc finger BED-type containing 5 |
| HMOX1 | heme oxygenase (decycling) 1 | ||
Patient characteristics – subjects with IgA nephropathy.
| Control | IgA nephropathy | |
| Number | 6 | 25 |
| Mean age(range) | 48.5(32–62) | 36(19–84) |
| % male | 50 | 71 |
| Mean serum creatinine ± SD (range)µmol/L | <120 | 131±129 (40–643) |
| Mean 24h urine protein ± SD (range)g/24h | <0.20 | 2.36±2.3 (0.28–10) |
Figure 1Cluster analysis.
Clustering of microarrays according to disease status (horizontal axis) based upon expression of the 231 albumin-regulated genes (vertical axis). Control = control group, IgAN = IgA nephropathy.
Validation gene set.
| Gene Title | Gene Symbol | Biological Process Description |
| collagen, type I, alpha 1 | COL1A1 | skeletal development, epidermis development |
| early growth response 1 | EGR1 | regulation of transcription, T cell differentiation |
| E74-like factor 3 (ets domain transcription factor,epithelial-specific) | ELF3 | regulation of transcription, epidermis development, morphogenesis |
| immediate early response 3 | IER3 | Anti-/apoptosis, morphogenesis |
| heparin-binding EGF-like growth factor | HBEGF | Signal transduction, EGFR signaling pathway, smooth muscle cell proliferation |
| v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian) | MAFF | transcription regulation, epidermal cell differentiation |
| myeloid cell leukemia sequence 1 (BCL2-related) | MCL1 | regulation of apoptosis, differentiation |
| sterile alpha motif domain containing 4A | SAMD4A | positive regulation of translation |
| serpin peptidase inhibitor (plasminogen activator inhibitor type 1)1 | SERPINE1 | blood coagulation, fibrinolysis, regulation of angiogenesis |
| six transmembrane epithelial antigen of the prostate 1 | STEAP1 | electron transport |
| Thymidylate synthetase | TYMS | nucleic acid metabolism/biosynthesis, DNA replication/repair, phosphoinositide-mediated signaling |
Patient characteristics – European Renal cDNA Bank glomerular disease subjects.
| FSGS | MGN | MCD | |
| Number | 10 | 18 | 5 |
| Mean age (range) | 50 (32–76) | 53 (18–86) | 45 (25–78) |
| % male | 60 | 56 | 80 |
| Mean serum creatinine ± SD (range)µmol/L | 156±105 (53–355) | 88.6±35.5 (40–160) | 101±42.5 (53–134) |
| Mean 24h urine protein ± SD (range)g/24h | 4.97±2.6 (1.9–8.4) | 4.58±3.2 (0.5–9.8) | 2.90±4.0 (0.1–5.7) |
*10 patients age available for only 4 patients.
**5 patients; age and serum creatinine available for only 3 patients.
Figure 2Cluster analysis.
Clustering of microarrays according to disease status (columns) based upon expression of the 11 albumin-regulated genes (rows). Control = control group, FSGS = focal segmental glomerulosclerosis, MGN = membranous GN, MCD = minimal change disease.
Figure 3Transcription factor analysis.
Green shade indicates the presence of a transcription factor binding site sequence, upstream from the gene of interest. Each row represents a gene of interest, and each column represents a putative transcription factor.